[go: up one dir, main page]

WO2003027094A3 - 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase - Google Patents

3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase Download PDF

Info

Publication number
WO2003027094A3
WO2003027094A3 PCT/US2002/030482 US0230482W WO03027094A3 WO 2003027094 A3 WO2003027094 A3 WO 2003027094A3 US 0230482 W US0230482 W US 0230482W WO 03027094 A3 WO03027094 A3 WO 03027094A3
Authority
WO
WIPO (PCT)
Prior art keywords
indazoles
substituted
pyridyl indoles
indoles
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/030482
Other languages
English (en)
Other versions
WO2003027094A2 (fr
Inventor
Gaetan H Ladouceur
Michael J Burke
Wai C Wong
Donald Bierer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to AU2002340010A priority Critical patent/AU2002340010A1/en
Priority to CA002461363A priority patent/CA2461363A1/fr
Priority to EP02778338A priority patent/EP1432698A2/fr
Priority to US10/491,214 priority patent/US20040236110A1/en
Priority to JP2003530682A priority patent/JP2005528325A/ja
Publication of WO2003027094A2 publication Critical patent/WO2003027094A2/fr
Publication of WO2003027094A3 publication Critical patent/WO2003027094A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des 3-pyridyl indoles et indazoles substitués, ainsi que des compositions pharmaceutiques contenant ces composés. L'invention concerne également des procédés d'utilisation de 3-pyridyl indoles et indazoles substitués, et de compositions pharmaceutiques contenant ces composés, en tant qu'inhibiteurs de lyases, par ex. de l'enzyme 17α-hydroxylase-C17,20-lyase. L'invention concerne par ailleurs des procédés de traitement du cancer chez un malade, consistant à administrer à un malade des 3-pyridyl indoles et indazoles substitués, ou une composition pharmaceutique contenant ces composés. Les cancers concernés par le traitement selon l'invention sont par ex. le cancer de la prostate ou le cancer du sein.
PCT/US2002/030482 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase Ceased WO2003027094A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002340010A AU2002340010A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
CA002461363A CA2461363A1 (fr) 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
EP02778338A EP1432698A2 (fr) 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
US10/491,214 US20040236110A1 (en) 2001-09-26 2002-09-26 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
JP2003530682A JP2005528325A (ja) 2001-09-26 2002-09-26 Ｃ１７，２０リアーゼ阻害剤としての置換３−ピリジルインドール類およびインダゾール類

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32499301P 2001-09-26 2001-09-26
US60/324,993 2001-09-26

Publications (2)

Publication Number Publication Date
WO2003027094A2 WO2003027094A2 (fr) 2003-04-03
WO2003027094A3 true WO2003027094A3 (fr) 2003-10-23

Family

ID=23265979

Family Applications (8)

Application Number Title Priority Date Filing Date
PCT/US2002/030982 Ceased WO2003027095A1 (fr) 2001-09-26 2002-09-26 3-pyridyl tetrazoles substitues en tant qu'inhibiteurs de la lyase c17,20 de la steroide
PCT/US2002/030983 Ceased WO2003027096A1 (fr) 2001-09-26 2002-09-26 3-pyridyl imidazoles substitues en tant qu'inhibiteurs de la lyase c17,20
PCT/US2002/030483 Ceased WO2003027085A2 (fr) 2001-09-26 2002-09-26 Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20
PCT/US2002/030834 Ceased WO2003027107A1 (fr) 2001-09-26 2002-09-26 3-pyridyl oxazoles substitues, inhibiteurs de la c17,20 lyase
PCT/US2002/030924 Ceased WO2003027100A1 (fr) 2001-09-26 2002-09-26 Inhibiteurs de lyase c17,20 a base de 3-pyridyle-pyrimidine substituee
PCT/US2002/030981 Ceased WO2003027105A1 (fr) 2001-09-26 2002-09-26 3-pyridyl thiophenes substitues en tant qu'inhibiteurs de la lyase c17,20
PCT/US2002/030482 Ceased WO2003027094A2 (fr) 2001-09-26 2002-09-26 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
PCT/US2002/030979 Ceased WO2003027101A1 (fr) 2001-09-26 2002-09-26 3-pyridyl pyrroles et 3-pyridyl pyrazoles substitues en tant qu'inhibiteurs de la lyase c17,20

Family Applications Before (6)

Application Number Title Priority Date Filing Date
PCT/US2002/030982 Ceased WO2003027095A1 (fr) 2001-09-26 2002-09-26 3-pyridyl tetrazoles substitues en tant qu'inhibiteurs de la lyase c17,20 de la steroide
PCT/US2002/030983 Ceased WO2003027096A1 (fr) 2001-09-26 2002-09-26 3-pyridyl imidazoles substitues en tant qu'inhibiteurs de la lyase c17,20
PCT/US2002/030483 Ceased WO2003027085A2 (fr) 2001-09-26 2002-09-26 Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20
PCT/US2002/030834 Ceased WO2003027107A1 (fr) 2001-09-26 2002-09-26 3-pyridyl oxazoles substitues, inhibiteurs de la c17,20 lyase
PCT/US2002/030924 Ceased WO2003027100A1 (fr) 2001-09-26 2002-09-26 Inhibiteurs de lyase c17,20 a base de 3-pyridyle-pyrimidine substituee
PCT/US2002/030981 Ceased WO2003027105A1 (fr) 2001-09-26 2002-09-26 3-pyridyl thiophenes substitues en tant qu'inhibiteurs de la lyase c17,20

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030979 Ceased WO2003027101A1 (fr) 2001-09-26 2002-09-26 3-pyridyl pyrroles et 3-pyridyl pyrazoles substitues en tant qu'inhibiteurs de la lyase c17,20

Country Status (5)

Country Link
EP (2) EP1432706A2 (fr)
JP (2) JP2005532983A (fr)
AU (2) AU2002340010A1 (fr)
CA (2) CA2461360A1 (fr)
WO (8) WO2003027095A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
AU2002221080A1 (en) * 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004110350A2 (fr) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Composes et leurs utilisations pour la modulation de l'amyloide-beta
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
CA2545719A1 (fr) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles et oxazoles utiles en tant que modulateurs de transporteurs de type cassette de liaison a l'atp
AU2005232745A1 (en) * 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
JP4602686B2 (ja) * 2004-04-15 2010-12-22 広栄化学工業株式会社 ２，６−ジハロゲノ−４−アリールピリジン類の製造法
EP2402323A3 (fr) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Composes pour la suppression de mutations non-sens et procedes d'utilisation associes
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
WO2006051723A1 (fr) * 2004-11-09 2006-05-18 Kaneka Corporation Méthode de synthèse de 1-halogéno-3-aryl-2-propanone
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
AU2005325497A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1932833B1 (fr) * 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Compose heterocyclique azote et composition pharmaceutique le contenant
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP2009523701A (ja) * 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
CA2636826C (fr) * 2006-01-18 2011-11-29 F.Hoffmann-La Roche Ag Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
EP1979314B1 (fr) * 2006-01-24 2013-01-09 Eli Lilly & Company Sulfamide d'indole modulateur de récepteurs de la progestérone
JP5249919B2 (ja) * 2006-03-29 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピリジン及びピリミジン誘導体
WO2008021338A2 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés d'oxazolidone tricycliques utiles en tant que modulateurs du récepteur de la progestérone
WO2008021337A1 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés oxazinan-2-one utiles comme modulateurs pr
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
ATE534642T1 (de) * 2006-09-21 2011-12-15 Eisai R&D Man Co Ltd Durch einen heteroarylring substituiertes pyridinderivat und antipilzmittel, das dieses enthält
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
JP2010505866A (ja) 2006-10-02 2010-02-25 コルテンド・インヴェスト・アクチボラゲット ヒトにおけるケトコナゾールエナンチオマー
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
MX2009012613A (es) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
KR101597665B1 (ko) 2007-08-13 2016-02-24 몬산토 테크놀로지 엘엘씨 선충류 방제용 조성물 및 방법
JP5567481B2 (ja) 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとして有用なピリジン誘導体
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
JP5584138B2 (ja) * 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US8563552B2 (en) 2008-02-08 2013-10-22 Shiseido Company Ltd. Whitening agent and skin external preparation
HUE060249T2 (hu) * 2008-06-16 2023-02-28 Univ Tennessee Res Found Vegyületek rák kezelésére
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US8697694B2 (en) * 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US20120010241A1 (en) * 2009-03-19 2012-01-12 Sanofi Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof
ES2759949T3 (es) * 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
WO2011051198A2 (fr) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés de pyridine en tant qu'agents phytoprotecteurs
DE102009058280A1 (de) * 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
EP2593453B1 (fr) 2010-07-15 2014-09-17 Bristol-Myers Squibb Company Composés azaindazole
KR101823275B1 (ko) 2010-08-04 2018-03-08 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
PH12013500723A1 (en) 2010-10-13 2017-08-23 Millennium Pharm Inc Heteroaryls and uses thereof
JP5953308B2 (ja) * 2010-10-22 2016-07-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺害虫剤としての新規ヘテロ環式化合物
AU2011320565A1 (en) * 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2638041B1 (fr) 2010-11-12 2015-07-22 Bristol-Myers Squibb Company Dérivés azaindole substitués
GB2485404A (en) * 2010-11-15 2012-05-16 Nat Univ Ireland Metal-complexed pyridyl-substituted tetrazole compounds and their use in treating cancer
CN102675286B (zh) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
WO2012162468A1 (fr) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Dérivés de thiazole en tant qu'inhibiteurs de pro-métalloprotéinases de matrice
EP2760870B1 (fr) 2011-09-27 2016-05-04 Bristol-Myers Squibb Company Composés d'hétéroaryle bicycliques substitués
WO2014055595A1 (fr) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Composés d'indoline utilisés comme inhibiteurs de l'aldostérone synthase et applications s'y rapportant
EP2934144B1 (fr) * 2012-12-20 2017-07-19 Merck Sharp & Dohme Corp. Composés d'indazole utiles comme inhibiteurs de l'aldostérone synthase
CA2904338C (fr) 2013-03-05 2022-07-05 University Of Tennessee Research Foundation Utilisation de derives de l'imidazole conjointement a un inhibiteur brafou a un inhibiteur mek dans le traitement du cancer
US20160022606A1 (en) 2013-03-14 2016-01-28 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
EP3191087A1 (fr) 2014-09-12 2017-07-19 Pellficure Pharmaceuticals, Inc. Compositions et méthodes de traitement d'un carcinome de la prostate
EP3528799A1 (fr) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Compositions pharmaceutiques de 5-hydroxy-2-méthylnaphtalène-1, 4-dione
JP7193071B2 (ja) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 蛍光発光材料および紫外線吸収剤
WO2021126779A1 (fr) * 2019-12-18 2021-06-24 The Regents Of The University Of California Inhibiteurs de lin28 et leurs méthodes d'utilisation
US20210246109A1 (en) * 2020-02-11 2021-08-12 University Of Kentucky Research Foundation Potent and selective inhibitors of cytochrome p450
WO2023049199A1 (fr) * 2021-09-24 2023-03-30 Zeno Management, Inc. Composés azole
CN117551029A (zh) * 2023-11-22 2024-02-13 河南大学 一种4-溴-3-氰基吡啶的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126401A1 (fr) * 1983-05-17 1984-11-28 Ciba-Geigy Ag Composés dérivés de l'indole
EP0544218A1 (fr) * 1991-11-25 1993-06-02 Sumitomo Chemical Company Limited Dèrives d'arylindazole et leur utilisation
WO1993015049A1 (fr) * 1992-01-22 1993-08-05 Zeneca Limited Derives de n-phenylindole et de n-pyridylindole, leur preparation et leur utilisation comme herbicides
WO1993018008A1 (fr) * 1992-03-09 1993-09-16 Zeneca Limited Nouveaux arylindazoles et leur utilisation comme herbicides
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
US5928998A (en) * 1992-03-09 1999-07-27 Zeneca Limited Arylindazoles and their use as herbicides
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150068C (da) * 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
JPS55133366A (en) * 1979-04-05 1980-10-17 Otsuka Pharmaceut Factory Inc Thiazole derivative
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
DE3940477A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Hetaryl-substituierte pyridinylpyrimidin-derivate
JPH04154773A (ja) * 1990-10-15 1992-05-27 Green Cross Corp:The チアゾール誘導体
DE4117560A1 (de) * 1991-05-29 1992-12-03 Bayer Ag Verwendung von pyridinylpyrimidin-derivaten zum schutz technischer materialien
KR980700077A (ko) * 1994-11-29 1998-03-30 나까토미 히로타카 2-아미노티아졸유도체 및 그 염류로 이루어진 항균제 또는 살균제(Antibacterial Prepartion or Bactericide comprising 2-Aminothiazole Derivative or Salt Thereof
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
AU732406B2 (en) * 1997-10-03 2001-04-26 Merck Frosst Canada & Co. Aryl thiophene derivatives as PDE IV inhibitors
EP1077958A1 (fr) * 1998-05-12 2001-02-28 American Home Products Corporation Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
AU5227999A (en) * 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
EP1261607B1 (fr) * 2000-03-01 2008-11-12 Janssen Pharmaceutica N.V. Derives de thiazolyle 2,4-disubstitue

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126401A1 (fr) * 1983-05-17 1984-11-28 Ciba-Geigy Ag Composés dérivés de l'indole
EP0544218A1 (fr) * 1991-11-25 1993-06-02 Sumitomo Chemical Company Limited Dèrives d'arylindazole et leur utilisation
WO1993015049A1 (fr) * 1992-01-22 1993-08-05 Zeneca Limited Derives de n-phenylindole et de n-pyridylindole, leur preparation et leur utilisation comme herbicides
US5395817A (en) * 1992-01-22 1995-03-07 Imperial Chemical Industries Plc N-arylindoles and their use as herbicides
WO1993018008A1 (fr) * 1992-03-09 1993-09-16 Zeneca Limited Nouveaux arylindazoles et leur utilisation comme herbicides
US5928998A (en) * 1992-03-09 1999-07-27 Zeneca Limited Arylindazoles and their use as herbicides
US6046136A (en) * 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DN GRIGORYEV, BJ LONG, IP NANE,VCO NJAR, Y LIU AND AMH BRODIE: "Effects of new 17alpha-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo", BRITISH JOURNAL OF CANCER, vol. 81, no. 4, 1999, pages 622 - 630, XP009001303 *
YAN ZHUANG AND ROLF W. HARTMANN: "Synthesis and Evaluation of Azole-substituted 2-Aryl-6-methoxy-3,4-dihydronaphthalenes and -naphthalenes as Inhibitors of 17 alpha-Hydroxylase-C17,20-Lyase (P450 17)", ARCH. PHARM. PHARM. MED. CHEM., vol. 332, 1999, pages 25 - 30, XP002222972 *

Also Published As

Publication number Publication date
WO2003027101A1 (fr) 2003-04-03
WO2003027105A1 (fr) 2003-04-03
EP1432698A2 (fr) 2004-06-30
CA2461360A1 (fr) 2003-04-03
WO2003027085A3 (fr) 2003-12-04
CA2461363A1 (fr) 2003-04-03
WO2003027107A1 (fr) 2003-04-03
JP2005532983A (ja) 2005-11-04
WO2003027085A2 (fr) 2003-04-03
WO2003027094A2 (fr) 2003-04-03
AU2002340010A1 (en) 2003-04-07
WO2003027095A1 (fr) 2003-04-03
WO2003027100A1 (fr) 2003-04-03
EP1432706A2 (fr) 2004-06-30
WO2003027096A1 (fr) 2003-04-03
JP2005528325A (ja) 2005-09-22
AU2002362603A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
WO2003027094A3 (fr) 3-pyridyl indoles et indazoles substitues servant d'inhibiteurs de c17,20 lyase
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
WO2005084295A3 (fr) Composes heterocycliques fusionnes utilises comme inhibiteurs de la 17b-hydroxysteroide dehydrogenase 3
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
TW200510416A (en) P38 inhibitors and methods of use thereof
SG170809A1 (en) Diarylthiohydantoin compounds
WO2005105780A3 (fr) Compositions utiles en tant qu'inhibiteurs de la rock et d'autres proteines kinases
TW200602052A (en) Azaindoles useful as inhibitors of JAK and other protein kinases
WO2005019190A3 (fr) Composes d'aminofurazan utiles comme inhibiteurs de proteine-kinases
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
PL356908A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
WO2002096361A3 (fr) Derives de 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone utilises comme inhibiteurs de kinase
CA2366932A1 (fr) Inhibiteurs cycliques de proteine tyrosine kinase
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002057261A3 (fr) Diaminothiazoles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002778338

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2461363

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10491214

Country of ref document: US

Ref document number: 2003530682

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002778338

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002778338

Country of ref document: EP